
 
 
 
 
 
 
 
 
 THE CLAIMS DEFINING THE INVENTION ARE AS FOLLOWS: 
   
 1. A method of inhibiting proliferation of prostate-specific membrane antigen (PSMA) expressing cancer cells, the method comprising: contacting PSMA-expressing cancer cells with an antiandrogen; and contacting the PSMA-expressing cancer cells with a PSMA ligand-anticancer agent conjugate; wherein the PSMA ligand of the conjugate comprises an antibody, or antigen-binding fragment thereof, that binds specifically PSMA, wherein the anticancer agent comprises a cytotoxic radionuclide; and wherein the PSMA-expressing cancer cells comprise PSMA-expressing cancer cells insensitive to antiandrogen therapy such that proliferation of the PSMA-expressing cancer cells was not affected by prior antiandrogen therapy alone. 
 
     
 2. The method of claim 1, wherein the antibody or antigen-binding fragment thereof is an antibody selected from the group consisting of: PSMA 3.7, PSMA 3.8, PSMA 3.9, PSMA 3.11, PSMA 5.4, PSMA 7.1, PSMA 7.3, PSMA 10.3, PSMA 1.8.3, PSMA A3.1.3, PSMA A3.3.1, Abgenix 4.248.2, Abgenix 4.360.3, Abgenix 4.7.1, Abgenix 4.4.1, Abgenix 4.177.3, Abgenix 4.16.1, Abgenix 4.22.3, Abgenix 4.28.3, Abgenix 4.40.2, Abgenix 4.48.3, Abgenix 4.49.1, Abgenix 4.209.3, Abgenix 4.219.3, Abgenix 4.288.1, Abgenix 4.333.1, Abgenix 4.54.1, Abgenix 4.153.1, Abgenix 4.232.3, Abgenix 4.292.3, Abgenix 4.304.1, Abgenix 4.78.1 and Abgenix 4.152.1, or an antigen-binding fragment thereof. 
 
     
 3. The method of claim 1, wherein the antibody or antigen-binding fragment thereof comprises (i) the three complementarity determining regions of a heavy chain variable region comprising an amino acid sequence set forth as SEQ ID NO:15 and (ii) the three complementarity determining regions of a light chain variable region comprising an amino acid sequence set forth as SEQ ID NO: 17. 
 
     
 4. The method of claim 1, wherein the antibody or antigen-binding fragment thereof comprises (i) the three complementarity determining regions of a heavy chain variable region comprising an amino acid sequence set forth as SEQ ID NO:19 and (ii) the three complementarity determining regions of a light chain variable region comprising an amino acid sequence set forth as SEQ ID NO: 21. 
 
     
 5. The method of claim 1, wherein the antibody or antigen-binding fragment thereof comprises (i) the three complementarity determining regions of a heavy chain variable region comprising an amino acid sequence set forth as SEQ ID NO:23 and (ii) the three complementarity determining regions of a light chain variable region comprising an amino acid sequence set forth as SEQ ID NO: 25. 
 
     
 6. The method of claim 1, wherein the antibody or antigen-binding fragment thereof comprises (i) the three complementarity determining regions of a heavy chain variable region comprising an amino acid sequence set forth as SEQ ID NO:27 and (ii) the three complementarity determining regions of a light chain variable region comprising an amino acid sequence set forth as SEQ ID NO: 29. 
 
     
 7. The method of claim 1, wherein the antibody or antigen-binding fragment thereof comprises (i) the three complementarity determining regions of a heavy chain variable region comprising an amino acid sequence set forth as SEQ ID NO: 31 and (ii) the three complementarity determining regions of a light chain variable region comprising an amino acid sequence set forth as SEQ ID NO: 33. 
 
     
 8. The method of claim 1, wherein the antibody or antigen-binding fragment thereof comprises (i) the three complementarity determining regions of a nucleic acid sequence set forth as SEQ ID NO:2 and (ii) the three complementarity determining regions of a nucleic acid sequence set forth as SEQ ID NO: 8. 
 
     
 9. The method of claim 1, wherein the antibody or antigen-binding fragment thereof comprises (i) the three complementarity determining regions of a nucleic acid sequence set forth as SEQ ID NO:3 and (ii) the three complementarity determining regions of a nucleic acid sequence set forth as SEQ ID NO: 9. 
 
     
 10. The method of claim 1, wherein the antibody or antigen-binding fragment thereof comprises (i) the three complementarity determining regions of a nucleic acid sequence set forth as SEQ ID NO:4 and (ii) the three complementarity determining regions of a nucleic acid sequence set forth as SEQ ID NO: 10. 
 
     
 11. The method of claim 1, wherein the antibody or antigen-binding fragment thereof comprises (i) the three complementarity determining regions of a nucleic acid sequence set forth as SEQ ID NO:5 and (ii) the three complementarity determining regions of a nucleic acid sequence set forth as SEQ ID NO: 11. 
 
     
 12. The method of claim 1, wherein the antibody or antigen-binding fragment thereof comprises (i) the three complementarity determining regions of a nucleic acid sequence set forth as SEQ ID NO:6 and (ii) the three complementarity determining regions of a nucleic acid sequence set forth as SEQ ID NO: 12. 
 
     
 13. The method of claim 1, wherein the antibody or antigen-binding fragment thereof is antibody PSMA 10.3, AB-PG1-XG1-006, AB-PG1-XG1-026, AB-PG1-XG1-051, AB-PG1 XG1-069, AB-PG1-XG1-077, or an antigen-binding fragment thereof. 
 
     
 14. The method of claim 1, wherein the antibody is antibody E99, J415, J533 or J591, or an antigen -binding fragment thereof. 
 
     
 15. The method of claim 1, wherein the antibody is 3F5.4G6, 3D7-1.1, 4E10-1.14, 1G3, 1G9, 2C7, 3C4, 3C6, 3C9, 3E6, 3E11, 3G6, 4D4, 4D8, 4C8B9, 3F6, 2E4, 3C2, 2D4, 4C8G8, 2C4, 4C11, ID11, 4E8, 2G5, 4E6, 1F4, 2E3, 3D8, 4F8, 3D2, 1G7, 3D4, 5G10 or 5E9, or an antigen-binding fragment thereof. 
 
     
 16. The method of any one of claims 1-15, wherein the cytotoxic radionuclide is alpha emitting. 
 
     
 2 2 5 Ac, 21 17. The method of claim 16, wherein the cytotoxic radionuclide is At, 2 12 Bi, 2 13 Bi, 2 12 22 4 223 P Ra, Ra. 
 
     
 18. The method of any one of claims 1-17, wherein the antiandrogen blocks enzyme cytochrome CYP17. 
 
     
 19. The method of any one of claims 1-17, wherein the antiandrogen is an androgen receptor antagonist. 
 
     
 20. The method of any one of claims 1-17, wherein the antiandrogen is abiraterone, enzalutamide, nilutamide, flutamide, bicalutamide, ARN 509, galeterone or orteronel. 
 
     
 21. The method of claim 20, wherein the antiandrogen is enzalutamide, abiraterone or ARN 509. 
 
     
 22. The method of any one of claims 1-21, wherein the antiandrogen is in an amount effective to upregulate PSMA expression. 
 
     
 23. The method of any one of claims 1-22, wherein the step of contacting the PSMA expressing cancer cells with the antiandrogen and the step of contacting the PSMA-expressing cancer cells with the PSMA ligand-anticancer agent conjugate are concurrent. 
 
     
 24. The method of any one of claims 1-22, wherein the step of contacting the PSMA expressing cancer cells with the antiandrogen and the step of contacting the PSMA-expressing cancer cells with the PSMA ligand-anticancer agent conjugate are sequential, wherein the step of contacting the PSMA-expressing cancer cells with the antiandrogen is prior to the step of contacting the PSMA-expressing cancer cells with the PSMA ligand-anticancer agent conjugate. 
 
     
 25. The method of claim 24, wherein the step of contacting the PSMA-expressing cancer cells with the PSMA ligand-anticancer agent conjugate occurs within one week of the step of contacting the PSMA-expressing cancer cells with the antiandrogen. 
 
     
 26. The method of any one of claims 1-25, wherein the PSMA-expressing cancer cells are in contact with the antiandrogen for at least 3 days. 
 
     
 27. The method of claim 26, wherein the PSMA-expressing cancer cells are in contact with the antiandrogen for at least 7 days. 
 
     
 28. The method of claim 27, wherein the PSMA-expressing cancer cells are in contact with the antiandrogen for at least 14 days. 
 
     
 29. The method of claim 28, wherein the PSMA-expressing cancer cells are in contact with the antiandrogen for at least 21 days or at least 28 days. 
 
     
 30. The method of any one of claims 1-29, wherein the PSMA-expressing cancer cells comprise androgen-independent PSMA-expressing cancer cells. 
 
     
 31. The method of any one of claims 1-30, wherein the PSMA-expressing cancer cells are of a tumor. 
 
     
 32. The method of any one of claims 1-31, wherein the PSMA-expressing cancer cells are PSMA-expressing prostate cancer cells. 
 
     
 33. The method of any one of claims 1-30, wherein the PSMA-expressing cancer cells are PSMA-expressing non-prostate cancer cells. 
 
     
 34. The method of claim 33, wherein the PSMA-expressing cancer cells are of the neovasculature of non-prostate cancer cells. 
 
     
 35. The method of any one of claims 1-34, wherein the PSMA-expressing cancer cells are of a subject. 
 
     
 36. The method of claim 35, wherein the subject has progressive metastatic castration resistant prostate cancer. 
 
     
 37. The method of claims 35 or claim 36, wherein the subject has had prior chemotherapy with at least one taxane. 
 
     
 38. The method of any one of claims 35-37, wherein the subject has prostate cancer that has progressed despite prior treatment. 
 
     
 39. The method of claim 35 or claim 36, wherein the subject has not had prior cytotoxic chemotherapy. 
 
     
 40. A composition comprising an antiandrogen and a PSMA ligand-anticancer agent conjugate each independently defined as in any one of claims 1-39. 
 
     
 41. The composition of claim 40, further comprising a pharmaceutically acceptable carrier and/or excipient. 
 
     
 42. The composition of claim 40 or claim 41, wherein the antiandrogen and/or the PSMA ligand-anticancer conjugate is in aqueous medium. 
 
     
 43. The composition of any one of claims 40-42, wherein the antiandrogen and/or the PSMA ligand-anticancer conjugate is lyophilized. 
 
     
 44. The composition of any one of claims 40-43, further comprising a diluent. 
 
     
 45. The composition of claim 43 or claim 44, further comprising instructions for reconstituting the antiandrogen and/or the PSMA ligand-anticancer conjugate. 
 
   
 
 
 
 
 
 
 
 
